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Objective: Myocardial ischemia and infarction after surgery remain leading causes of morbidity and mortality in patients
undergoing major vascular surgery. B-type natriuretic peptide has been shown to predict early postoperative cardiac
events in patients undergoing major noncardiac surgery. We aimed to determine if N-terminal pro B-type natriuretic
peptide (NT-pro-BNP), with its longer half-life and greater plasma stability, can predict postoperative myocardial injury
in vascular patients.
Methods: Recruited were 136 patients undergoing elective surgery for subcritical limb ischemia or abdominal aortic
aneurysm (AAA) repair. Plasma NT-pro-BNP was measured preoperatively, and troponin-I was measured immediately
after surgery and on postoperative days 1, 2, 3, and 5.
Results: Twenty-eight patients (20%) sustained postoperative myocardial injury (troponin-I rise of >0.1 ng/mL). The
median NT-pro-BNP level of those with myocardial injury was significantly higher than those who did not (380 pg/mL
[interquartile range (IQR), 223-967] vs 209 pg/mL [109-363]; P  .003). NT-pro-BNP predicted this outcome with
an area under the receiver operating characteristic (ROC) curve of 68% (95% confidence interval [CI] 0.56%-0.78%). In
a multivariate analysis, a NT-pro-BNP value of >308 pg/mL (the optimal ROC curve– derived cutoff) was associated
with an increased incidence of myocardial injury (odds ratio, 3.4; 95% CI, 1.41-9.09, P .01).
Conclusion: Elevated preoperative plasma NT-pro-BNP levels independently predict postoperative myocardial injury,
which is associated with adverse outcome in the short- and long-term regardless of the presence of symptoms of acute
coronary syndrome. ( J Vasc Surg 2008;48:912-7.)Major vascular surgery is associated with a high risk of
early cardiovascular complications.1-3 Myocardial injury, as
detected by a rise in the troponin-I concentration, has been
shown to occur in up to 20% of patients undergoing
elective aortic aneurysm repair and 38% of patients under-
going revascularization for critical limb ischemia.4,5 Post-
operative myocardial injury is asymptomatic in most pa-
tients.6-8 However, even early small postoperative rises in
troponin-I have been shown to correlate with adverse
short- and medium-term outcome.6,9-13
A means of identifying patients at risk of a postoperative
rise in troponin may facilitate targeted perioperative inter-
ventions and optimize the use of limited resources. Preop-
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912erative risk stratification guidelines for patients undergoing
noncardiac surgery do not include important vascular prog-
nostic markers such as C-reactive protein.14 Furthermore,
the low predictive value of noninvasive testing of cardiac
function, coupled with limited resources, highlights the
need for alternative methods of predicting cardiac injury in
patients who are scheduled for major vascular surgery.15
Recent interest has focused on the possible role of
B-type natriuretic peptide (BNP) and its N-terminal frag-
ment (NT-pro-BNP) as predictors of early postoperative
adverse cardiac events in patients undergoing noncardiac
surgery.16-22 The major source of BNP synthesis and secre-
tion is the ventricular myocardium. In vascular patients NT-
pro-BNP has been shown to be an independent predictor of
30-day postoperative cardiac events as assessed by a composite
end point of symptoms, troponin-T levels, and electrocardio-
graph (ECG) recordings.21 In this study we aimed to deter-
mine if NT-pro-BNP can predict early postoperative myocar-
dial injury as assessed by a rise in troponin-I in patients
undergoing elective major vascular surgery.
METHODS
Study population. Recruited were 136 patients who
were scheduled to undergo elective surgery for revascular-
ization for subcritical limb ischemia (n  112) character-
ized by rest pain, ulcer, or gangrene, regardless of absolute
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inal aortic aneurysm (AAA, n 24) at the Vascular Unit of
Aberdeen Royal Infirmary. During the 21-month recruit-
ment period, 18 patients did not fulfil the criteria and were
excluded, a further five patients agreed to participate in the
study but did not proceed to surgery, and one patient
withdrew. Ethical approval was obtained from the Gram-
pian Regional Ethical Committee, and written informed
consent was obtained from each patient.
Exclusion criteria were patients with acute limb isch-
emia, current active infections; those taking antiplatelet
agents than aspirin, or other nonsteroidal anti-inflamma-
tory drugs, or anticoagulants like warfarin; and those with
symptomatic or ruptured AAA. Patients unable to give
informed consent were also excluded.23
Data from the study patients have been reported previ-
ously.23,24 All patients were receiving statin drugs before
surgery and aspirin therapy (75 mg/d), which was contin-
ued in the perioperative period. Documented were the
patients’ comorbidities, cardiac medications, and Revised
Cardiac Risk Index (RCRI),25 which includes the risk
factors of type of surgery, history of ischemic heart disease,
presence of signs of congestive cardiac failure, history of
cerebrovascular disease, need for insulin therapy, and a
preoperative serum creatinine level 2 mg/dL (177
mmol/L). Patients with 0, 1, 2, and 3 or more of these risk
factors are assigned to classes I, II, III, and IV, respectively.
Routine preoperative cardiac stress testing was not per-
formed in these patients.
Study design. The study was a prospective observa-
tional study of patients undergoing major elective vascular
surgery. Venous blood samples were collected from all
patients at baseline before surgery, immediately after sur-
gery, and on postoperative days 1, 2, 3, and 5 for measure-
ment of troponin-I. The baseline blood sample for NT-
pro-BNP assay, drawn the day before surgery, was
centrifuged and plasma stored in aliquots at 80°C. Re-
cordings of comorbidities, current smoking, cardiac medi-
cations, and clinical symptoms on a standardized data sheet
were performed along with a daily 12-lead ECG from the
day before surgery until 5 days after surgery. The ECGs
were interpreted by a consultant cardiologist who was
blinded to the troponin-I and NT-pro-BNP levels.
Cardiac troponin-I. Troponin-I was measured using
the Bayer ADVIA Centaur Immunoassay analyzer (Bayer
Diagnostics, Tarrytown, NY). This chemiluminometric
sandwich immunoassay has intra-assay coefficients of vari-
ation (CV) of 1.1% and 2.2% at levels of 2.9 ng/mL and 7.1
ng/mL, respectively. A troponin-I level of0.1 ng/mL on
this assay was considered elevated.13,19 The assays were
performed by the Department of Clinical Biochemistry,
NHS Grampian.
N-terminal pro B-type natriuretic peptide. The
Roche Elecsys N-terminal pro B-type natriuretic peptide
electrochemiluminescence sandwich immunoassay was per-
formed on a Roche Elecsys 2010 automated immunoassay
analyser platform (Roche Diagnostics, Basel, Switzerland).
The assay has an analytical sensitivity (lower detectionlimit) of 5 pg/mL and an effective measuring range of 5 to
35,000 pg/mL. The within-run CV was 2.7% at a concen-
tration of 175 pg/mL and 1.9% at 1068 pg/mL. Total
analytical precision demonstrated a CV of 3.2% and 2.6% at
concentrations of 175 and 1068 pg/mL, respectively.
Statistical analysis. Data are presented as medians
with interquartile ranges (IQR), and significance is devel-
oped at the 5% probability level. Differences between two
independent categoric values were tested with 2 test, and
differences between two continuous independent values
were tested with the Mann-Whitney U test. To test the
strength of the association between NT-pro-BNP and the
other continuous variables, the Spearman test for correla-
tion was used. A receiver operating characteristic (ROC)
curve was plotted to assess the ability of NT-pro-BNP to
predict postoperative myocardial injury, and the area under
the curve, with 95% confidence interval (CIs) was calcu-
lated. Multivariate logistic regression analysis was per-
formed to determine the independent predictive value of
NT-pro-BNP and other univariate predictors. Analysis was
done with SPSS 15 software (SPSS Inc, Chicago, Ill).
Power calculation. Our original study23 was powered
on the basis of a projected elevation of cardiac troponin in
24% of our 136 patients. The log-transformed NT-pro-
BNP data (parametric) were used for power calculation for
this article. The power of the study was calculated to be 87%
for the mean difference of 0.28 in the log NT-pro-BNP
level to be statistically significant at 5% level between the 28
patients who sustained myocardial injury and the 108 pa-
tients without injury. This is equivalent to a change from
238 to 436 pg/mL in the original NT-pro-BNP values.
RESULTS
The patient characteristics are reported in Table I. In
all patients, the preoperative troponin-I level was 0.10
ng/mL. A postoperative myocardial injury, defined as a
troponin-I 0.1 ng/mL, was noted in 28 patients
(20%), which occurred 48 hours of surgery in 23
(82%). One patient died on postoperative day 2 of a
cerebrovascular accident. None of the study patients had
typical ECG changes of acute myocardial infarction in
the postoperative period. Thirty-nine patients (28%)
were taking -adrenoceptor antagonists. The incidence
of postoperative myocardial injury was similar in patients
who were and were not taking -blockers (P  .65).
The median (IQR) NT-pro-BNP levels in patients who
sustained myocardial injury were significantly higher than
levels in those who did not (436 [275-1024] pg/mL vs
238 [111-435] pg/mL; P .003; Fig 1). This finding was
apparent in patients with subcritical limb ischemia (717.5
[366.35-1479] pg/mL vs 246 [120.57-506.82] pg/mL)
and those with AAA (319 [87.5-441] pg/mL vs 126.85
[84.9-265.72] pg/mL).
The incidence of troponin-I elevation in the 28 patients
increased with higher quartiles of NT-pro-BNP as follows:
quartile 1 (117 pg/mL) in 5; quartile 2 (117 to 280
pg/mL) in 2; quartile 3 (280 to 566 pg/mL) in 9; and
quartile 4 (566 pg/mL) in 12 (P  .01). Preoperative
ative NT-pro-BNP value than those who did not (P  .003).
IQR, inter-quartile range.
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P  .001) and peak postoperative troponin-I levels (r 
0.29, P  .001). No correlation was found between pre-
operative NT-pro BNP levels and the RCRI or preoperative
ECG findings.
The ability of NT-pro-BNP to predict postoperative
myocardial injury from the ROC curve was 68% (95% CI,
56%-78%, P  .005; Fig 2). An optimal cutoff point of
308 pg/mL was derived with a sensitivity of 71% and
specificity of 65% for predicting postoperative myocar-
dial injury (Fig 2). The positive-predictive value (PPV)
was 33% and negative-predictive value (NPV) 90%.
On univariate analysis, NT-pro-BNP levels as a contin-
uous variable and at a cutoff value of 308 pg/mL, along
with age and the RCRI, were significantly associated with
an elevated troponin-I level (Table I). Age was included in
the multivariate analysis despite its linear relationship to
NT-pro-BNP because the correlation coefficient was only
0.4. On multivariate analysis, after adjustment for cardiac
risk factors, only a preoperative NT-pro-BNP level 308
pg/mL remained an independent predictor of myocardial
injury (Table II).
DISCUSSION
This study demonstrates that the preoperative NT-pro-
nts with and without myocardial injury
Myocardial injury
Yes No P
28 108
73 (49-97) 68 (43-87) .015
18 (64) 74 (69) .65
18 (64) 67 (62) .56
9 (32) 29 (27) .37
21 (75) 83 (76)
2 (7) 7 (6)
2 (7) 8 (7) .55
3 (10) 10 (9)
14 (50) 75 (69)
14 (50) 33 (31)
4 (14) 12 (11) .056
9 (32) 30 (27) .65
11 (39) 28 (26) .16
9 (32) 29 (27) .57
4 (14) 11 (10) .53
3 (7) 39 (93)
14 (22) 47 (78)
9 (32) 19 (67)
2 (40) 3 (60) .04
94 (80-108) 97 (67-117) .94
1 (3.5) 4 (3.7) .97
436 (275-1024) 238 (111-435) .003
20 (71) 38 (35) .001
iuretic peptide; MI, myocardial infarction; OHA, oral hyperglycemic agent;Fig 1. The data for log-transformed N-terminal pro B-type natri-
uretic peptide (NT-pro-BNP) levels in patients who have myocar-
dial injury after surgery, compared with those who do not, are
shown in box and whisker plots. The horizontal line in the center of
the box represents the median; the top and bottom borders of the
box represent the interquartile range, and the whiskers mark the
range. The y axis represents the log-transformed NT-pro-BNP,
which was used in the power calculation. Patients who sustained
postoperative myocardial injury had a significantly higher preoper-Table I. Patient characteristics in the entire cohort and in patie
Variable
No (%) or median (IQR) Study population
Patients 136
Age, years 69 (43-97)
Male 92 (68)
Hypertension 85 (63)
Current smokers 38 (28)
Diabetes mellitus
None 104 (76)
Diet controlled 9 (6)
OHA treatment 10 (7)
Insulin treatment 13 (10)
Ischemic heart disease
None 89 (66)
Angina/previous MI 47 (34)
Previous cardiac revascularization 16 (12)
Cardiac medication
-blockers 39 (28)
ACE inhibitors 38 (28)
Calcium-channel blockers 38 (28)
Nitrates 15 (11)
Revised Cardiac Risk Index
I 42
II 61
III 28
IV 5
Creatinine, mol/L 94 (84-109)
Creatinine 177 mol/L 5 (3)
NT-pro-BNP, pg/mL 277 (117-561)
NT-pro-BNP 308 pg/mL 58 (42)
ACE, Angiotensin-converting enzyme; NT-pro-BNP, N-terminal pro B-type natrBNP level is an independent predictor of postoperative
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surgery. An asymptomatic postoperative troponin-I level
0.10 ng/mL occurred in 20% of our patients. This was
not accompanied by ECG changes. However, previous
studies have shown that a rise in troponin-I of this magni-
tude, with or without accompanying symptoms or ECG
changes, correlates with adverse short- and medium-term
survival.9-13 In this study a cutoff value of NT-proBNP of
308 pg/mL identified patients with a greater than three-
fold increased risk of myocardial injury in the early postop-
erative period. Thus, preoperative NT-pro-BNPmay have a
role in identifying high-risk vascular patients who may
require more extensive preoperative and postoperative car-
diovascular optimization and might be used as a screening
test for risk stratification in patients undergoing elective or
Fig 2. A receiver operating characteristic curve was calculated for
the ability of the preoperative plasma N-terminal pro B-type natri-
uretic peptide level to predict postoperative cardiac events in the
elective vascular surgical cohort. The horizontal axis represents the
false-positive ratio (1 minus specificity), and the vertical axis rep-
resents the true-positive ratio (sensitivity). The area under curve,
which measures discrimination (ie, the ability of the test to cor-
rectly classify those with and without myocardial injury), was 68%
(95% confidence interval, 56%-78%, P  .005).
Table II. Multivariate analysis to assess independent
predictors of myocardial injury
Predictor OR 95% CI P
Age, years 1.04 0.98-1.10 .12
Revised Cardiac Risk Index .075
I 1
II 3.41 0.89-13.71 .07
III 6.57 1.47-29.33 .01
IV 8.47 0.90-9.71 .06
NT-pro-BNP 308 pg/mL 3.41 1.27-9.09 .01
CI, Confidence interval; NT-pro-BNP, N-terminal pro B-type natriuretic
peptide; OR, odds ratio.semielective vascular surgery.Our group has previously shown that BNP levels of
40 pg/mL are predictive of perioperative death or myo-
cardial injury 72 hours of surgery in patients undergoing
noncardiac procedures.19 This study included 20 patients
undergoing major vascular surgery who were also included
in the current study. We assessed NT-pro-BNP in the
current cohort because the half-life of BNP is 20 minutes,
whereas NT-pro-BNP has a half-life of 120 minutes.26
Furthermore, the stability of NT-pro-BNP in stored plasma
is superior to that of BNP.27 NT-pro-BNP values are
approximately six times higher than the BNP levels,26 and
interestingly, the optimum cutoff value for NT-pro-BNP in
the current study is just slightly more than six times the
cutoff value obtained in our earlier work on a more heter-
ogeneous cohort using BNP (40 pg/mL).18 In both stud-
ies we found a positive linear relationship between NT-pro-
BNP and age.
Previous studies. A single prior study has assessed the
early predictive value of NT-pro-BNP in vascular pa-
tients.21 This also concluded that, as a continuous variable,
NT-pro-BNP was not an independent predictor of periop-
erative outcome.21 However, Feringa et al21 found that a
value of 533 pg/mL was independently associated with an
increased risk of early cardiac events, defined as a compo-
site end point of two or more of the following: elevated
troponin-T or creatine kinase (or both), ECG changes, and
ischemic symptoms. In this cohort the median concentra-
tion of baseline NT-pro-BNP was 110 pg/mL, which is
considerably lower than our study. The same investigators
have also demonstrated that preoperative NT-pro-BNP
levels predict medium-term mortality and major adverse
cardiac events with an optimal cutoff of 319 pg/mL.28
More recently, Mahla et al22 detected baseline NT-pro-
BNP levels similar to our study, and their patients had a
cardiac event rate of 20% during a median follow-up of 826
days. They also found that a NT-pro-BNP value 280
pg/mL was associated with a fourfold relative risk of ad-
verse cardiac events during medium-term follow-up.
Study limitations. In this study we have not shown
that NT pro-BNP levels are associated with an adverse
outcome, but that they are associated with a rise in tropo-
nin, which in turn is known to correlate with adverse
outcome. We do intend to monitor this cohort of patients
to determine their short- and medium-term outcome, but
at this current time, these data are not available.
Furthermore in this study, we have not shown a corre-
lation between NT-pro-BNP levels and various comorbidi-
ties such as diabetes, which is likely to be a reflection of
study numbers. Currently, the use of -blockers in the
perioperative period in patients undergoing vascular sur-
gery is not routine practice in the United Kingdom. De-
spite the perceived potential benefits of -blockers, the
significant incidence of bradycardia and hypotension has
led to the recommendation that there is a need for a suitably
powered randomized, controlled trial of perioperative
-blockers to definitively establish the benefits and risks.29
Results of the PeriOperative ISchemic Evaluation (POISE)
trial, a randomized, controlled trial using metoprolol vs
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lished.
Clinical implications. The main clinical utility of NT-
pro-BNP in this setting appears to be a very high NPV for
early postoperative events. In the current study we found a
NPV of 90% using our optimal cutoff value. This accords
with prior reports of a NPV of 100% in patients undergoing
a variety of noncardiac surgical procedures16 and 99% in
patients undergoing major vascular surgery.21 Likewise,
Feringa et al21 found that NT-pro-BNP was superior to
dobutamine stress echocardiography in identifying patients
at risk of cardiac events,21 and in the current study we have
shown it to be superior to the RCRI. No patients in this
study were readmitted with a cardiac event in the period
between hospital discharge and the first follow-up outpa-
tient visit. Data on medium term follow-up is not yet
available.
CONCLUSIONS
This study has shown that preoperative NT-pro-BNP
(using a cutoff value of 308 pg/mL) is an independent
predictor of postoperative myocardial injury in patients
undergoing vascular surgery. An asymptomatic postopera-
tive rise in troponin-I has been shown to correlate with
adverse short- and medium-term outcome. There is no
current consensus on the optimum cutoff value for NT-
pro-BNP, and further work is required in this area. Ulti-
mately, there is the potential to identify patients at in-
creased risk who may benefit from more aggressive
investigation and monitoring in the pre and postoperative
period.
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and Mr Edwin Amalraj (Department of Public Health,
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Mr Rajagopalan and coauthors have shown that an increased
level of N-terminal pro B-type natriuretic peptide (NT-pro-BNP)
detected preoperatively in arterial surgery patients is associated
with an increased likelihood of a postoperative rise to0.1 ng/mL
in the troponin-I level. From this finding, they conclude that
measuring NT-pro-BNP may identify patients at increased risk for
perioperative cardiac events who might benefit from more aggres-
sive preoperative investigation and treatment, as well as more
diligent postoperative monitoring.
Although a reliable serummarker for increased risk of clinically
relevant perioperative cardiac events would be very useful in car-
diac risk stratification and management, it remains doubtful
whether NT-pro-BNPwill meet this need. First, in this study, none
of the patients suffered a clinically apparent cardiac event or even
electrocardiogram changes. Even though troponin leaks have been
predictive of increased risk for adverse cardiac events in other
studies, no such events occurred during the limited follow-up in
this study. Therefore, from this study’s data, it remains unknownthe authors give no data on the magnitude of the troponin eleva-
tions, so it is impossible to gauge the severity of the clinically silent
myocardial injury associated with elevated NT-pro-BNP levels and
also to determine if the magnitude of the NT-pro-BNP elevation is
proportional to themagnitude of themyocardial injury. Third, and
most importantly, NT-pro-BNP elevation is neither highly sensi-
tive nor specific in predicting troponin leak. Of the 28 patients with
a rise in troponin, 8 (29%) did not have an elevated NT-pro-BNP,
and of the 108 patients without a rise in troponin, 38 (35%) had an
elevated BNP. Thus, the optimal threshold NT-pro-BNP value of
308 pg/mL, derived from a receiver-operator characteristic curve,
yields only 71% sensitivity and 65% specificity in predicting myo-
cardial injury.
Therefore, although this study is interesting, it should be
considered preliminary.Muchmore work is needed to establish the
clinical utility of preoperative NT-pro-BNP levels in predicting
adverse outcomes following vascular surgery. A reliable preopera-
tive serum marker for predicting adverse cardiac outcomes follow-
ing vascular surgery remains elusive.
